Treatmentemerging

Tesamorelin Therapy

A GHRH analog FDA-approved for HIV-associated visceral fat, marketed off-label by longevity clinics for reducing visceral/abdominal fat, body recomposition and cognitive/anti-aging benefits.

A GHRH analog FDA-approved for HIV-associated visceral fat, marketed off-label by longevity clinics for reducing visceral/abdominal fat, body recomposition and cognitive/anti-aging benefits. Sold as an injectable protocol.

Evidence

emerging

Strong human RCT evidence exists for reducing visceral fat in HIV lipodystrophy, but for the general anti-aging/longevity population the benefit is off-label and only emerging rather than established.

Regulatory notes

European Union
Not broadly authorised by the EMA for its US indication and not approved for longevity use; access is largely unlicensed/off-label.
United States
FDA-approved (Egrifta/Egrifta WR) ONLY for HIV-associated lipodystrophy; longevity and general body-composition use is off-label prescribing.
United Arab Emirates
Would require DHA/DoH-licensed prescribing; not registered for anti-aging indications.
United Kingdom
No general MHRA anti-aging authorisation; only lawful off-label or via unlicensed import under specialist prescription.

General information, not medical or legal advice. See our disclaimer.

Also known as

Egrifta, Egrifta SV, Egrifta WR, tesamorelin acetate, TH9507

Where to find it

40 clinics in the directory offer tesamorelin therapy. Prices shown are the cheapest for this treatment where published; always confirm with the venue.

Back to glossary